Close Menu

NEW YORK (GenomeWeb) – Multi-gene panel testing can identify patients who are carriers of pathogenic variants who might otherwise be missed under current genetic testing guidelines, according to a new study from Color researchers.

Current guidelines, such as the ones from the National Comprehensive Cancer Network (NCCN), recommend genetic testing for people who have a personal or family history of cancer that indicates they might be at an increased risk of harboring a pathogenic familial variant. But this approach could miss people who lack any personal or family history.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Dec
02
Sponsored by
Qiagen

The Phosphoinositide 3-Kinase (PI3K) pathway is one of the most frequently altered pathways in human cancer and plays a significant role in disease progression and resistance to endocrine therapy.